You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Telangana to get priority in Bharat Biotech's Covid-19 vaccine supply: KCR

Telangana CM K Chandrashekhar Rao said his government was ensuring that Telangana, as the home state, gets priority in supply of Covid-19 vaccine as and when it is manufactured by Bharat Biotech

Coronavirus Vaccine | Telangana | Coronavirus

IANS  |  Hyderabad 

Telangana Rashtra Samithi (TRS) president K Chandrashekar Rao (KCR) during his swearing-in ceremony as the Chief Minister of Telangana, in Hyderabad, Thursday | Photo: PTI
K Chandrashekar Rao | Photo: PTI

Chief Minister K. Chandrashekhar Rao on Wednesday said his government was ensuring that Telangana, as the home state, gets priority in supply of Covid-19 vaccine as and when it is manufactured by Hyderabad-based

He told the state Assembly that the government will talk to the company and will ensure that gets priority.

"We will talk to Definitely, it's a home state and if vaccines are made here, we will get first priority. There should be no doubt. We are ensuring this," he said.

The Chief Minister gave the assurance when All India Majlis-e-Ittehadul Muslimeen (AIMIM) leader Akbaruddin Owaisi raised the issue during a discussion on the Covid situation in the state.

Stating that Phase-2 clinical trials of Bharat Biotech's vaccine have started, Owaisi said should have some share if the vaccine is produced here. "The work is being done here. Telangana should have some share," he said.

Owaisi lauded the research being done by and said the company placed Hyderabad on the world health map.

India's first indigenous vaccine, Covaxin developed by Hyderabad-based Bharat Biotech, has successfully completed Phase-1 trials and the Centre has given its approval for Phase-2 trials.

The vaccine is likely to be launched in early 2021.

Bharat Biotech had announced on June 29 that it successfully developed Covaxin in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccineAcandidate has been developed and manufactured in Bharat Biotech's high containment facility located in Genome Valley, Hyderabad.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 09 2020. 18:57 IST